Abstract
We read with great interest the recent contribution of Dr. Kitta et al. in their study, entitled “Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder” [1]. They showed that treatment with vibegron significantly improved clinical and urodynamic parameters of pediatric OAB with no adverse effects. However, we would like to contribute some points regarding their paper.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
